Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL

Non-Hodgkin lymphoma (NHL) is the third most common malignancy diagnosed in children. The vast majority of paediatric NHL are either Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), anaplastic large cell lymphoma (ALCL), or lymphoblastic lymphoma (LL). Multi-agent chemotherapy is used t...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2021-11, Vol.13 (23), p.6003
Main Authors: Hare, Lucy, Burke, G. A. Amos, Turner, Suzanne D.
Format: Article
Language:English
Subjects:
ABC transporters
Anaplastic large-cell lymphoma
Antigens
Apoptosis
B-cell lymphoma
Burkitt's lymphoma
Cell division
Chemotherapy
Children
Disease
Drug resistance
Gene amplification
Gene expression
Kinases
Lymphocytes
Lymphocytes B
Lymphoma
Malignancy
Non-Hodgkin's lymphoma
Pathogenesis
Pediatrics
Protein-tyrosine kinase
Review
Side effects
Stem cells
Toxicity
Transplants & implants
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Non-Hodgkin lymphoma (NHL) is the third most common malignancy diagnosed in children. The vast majority of paediatric NHL are either Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), anaplastic large cell lymphoma (ALCL), or lymphoblastic lymphoma (LL). Multi-agent chemotherapy is used to treat all of these types of NHL, and survival is over 90% but the chemotherapy regimens are intensive, and outcomes are generally poor if relapse occurs. Therefore, targeted therapies are of interest as potential solutions to these problems. However, the major problem with all targeted agents is the development of resistance. Mechanisms of resistance are not well understood, but increased knowledge will facilitate optimal management strategies through improving our understanding of when to select each targeted agent, and when a combinatorial approach may be helpful. This review summarises currently available knowledge regarding resistance to targeted therapies used in paediatric anaplastic lymphoma kinase (ALK)-positive ALCL. Specifically, we outline where gaps in knowledge exist, and further investigation is required in order to find a solution to the clinical problem of drug resistance in ALCL.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13236003